Thomas Yau

机构：Queen Mary Hospital, University of Hong Kong · ORCID：0000-0002-7114-0305

发表论文 328 篇 · 总被引 25243 次 · h-index 66

代表论文

• Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial (2025 · The Lancet · 被引 338)
• The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment (2025 · The Lancet · 被引 194)
• Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW. (2024 · Journal of Clinical Oncology · 被引 151)
• APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024 (2024 · Hepatology International · 被引 66)
• Three-year follow-up data from KEYNOTE-966: Pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) compared with gem/cis alone for patients (pts) with advanced biliary tract cancer (BTC). (2024 · Journal of Clinical Oncology · 被引 42)
• Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (2024 · Journal of Hepatology · 被引 41)